Improving the design process with Rayon V3, an all-in-one architectural tool integrating AI, data, and collaborative ...

Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemiasFindings underscore ...

March Bio is continuing enrollment in the Phase 2 trial, with the Independent Data Monitoring Committee's approval to advance to Simon Stage 2 of the Phase 2 trial. The Company anticipates presenting ...

Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system ...

XTI Aerospace ( ($XTIA) ) has shared an announcement. On December 4, 2025, XTI Aerospace, Inc. released an investor presentation on its website ...

Studies Demonstrate xCellSense® Platform's Ability to Predict Clinical Response and Enable Patient Stratification for Drug Development.

Hand in hand with transparency is accountability. Promises about how data will be used only matter if they’re kept.

Photo from Freepik We make critical decisions that shape our company’s direction. Hiring. Training investments. Restructuring ...

Terns Pharmaceuticals, Inc. ( TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia December 8, 2025 4:30 PM EST ...

Experts say lack of mandate staff and awareness limits NSC’s role as recommendations highlight need for autonomy better standards audit systems and improved access to official datasets ...

Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion ...